PROF Earnings

PROF reported its earnings on 2026-05-07, showcasing a revenue of 5.34M against an estimate of 5.09M, resulting in a 4.85% surprise. The EPS was -0.19, surpassing the expected -0.24 by 20.83%. The stock experienced a -4.33% price change on the earnings day and a -0.84% change over the next five days, reflecting market reactions to the results.

Following PROF's earnings announcement on 2026-05-07, the stock price moved by -4.33% on the day of the release. Over the subsequent five days, it saw a -0.84% change. Historically, PROF's stock price tends to shift by an average of -1.48% in the 10 days leading up to earnings and -6.74% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate PROF's annual revenue to reach 7.78M, while the EPS is projected at -0.26. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PROF's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PROF's stock price typically moves by -1.48% in the 10 days before its earnings and -6.74% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.26 and revenue of 7.78M.

The earnings call presented strong financial performance with a 104% revenue increase YoY and improved gross margins. Despite a net loss, the reduction is notable. The Q&A highlighted a strong sales pipeline and positive reimbursement rates from private payers. While guidance was conservative, the company's bullish outlook and solid pipeline suggest potential growth. The market's response may be positive, especially with the anticipation of guideline recognition and commercial payer coverage. However, challenges in MR system integration and competitive pressures should be monitored. Overall, the sentiment leans towards a positive stock price movement.